Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TFBS BioscienceROCO:6939 -4.19%48 PB Ratio is 0.59 as of Aug. 06, 2026, which is 37% below its 10-year median of 0.93. GuruFocus rates ROCO:6939 with a GF Score™ of 48/100 and a GF Value™ of NT$31.94 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 195 Medical Diagnostics & Research companies, TFBS Bioscience ranks better than 91.79% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-08-06), TFBS Bioscience's share price is NT$19.45. TFBS Bioscience's Book Value per Share for the quarter that ended in Dec. 2025 was NT$33.24. Hence, TFBS Bioscience's PB Ratio of today is 0.59.
The historical rank and industry rank for TFBS Bioscience's PB Ratio or its related term are showing as below:
ROCO:6939'
s PB Ratio Range Over the Past 10 Years
Min: 0.57 Med: 0.93 Max: 1.94
Current: 0.58
During the past 6 years, TFBS Bioscience's highest PB Ratio was 1.94. The lowest was 0.57. And the median was 0.93.
ROCO:6939's PB Ratio is ranked better than 91.79% of 195
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06
vs ROCO:6939: 0.58
During the past 12 months, TFBS Bioscience's average Book Value Per Share Growth Rate was -5.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -2.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 36.60% per year.
During the past 6 years, the highest 3-Year average Book Value Per Share Growth Rate of TFBS Bioscience was 72.00% per year. The lowest was -2.20% per year. And the median was 42.50% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
TFBS Bioscience PB Ratio Related Terms
TFBS Bioscience PB Ratio Historical Data
* Premium members only.
The historical data trend for TFBS Bioscience's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, TFBS Bioscience's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TFBS Bioscience PB Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, TFBS Bioscience's PB Ratio distribution charts can be found below:
* The bar in red indicates where TFBS Bioscience's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
TFBS Bioscience's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
TFBS Bioscience (ROCO:6939) has a PB Ratio of 0.59 as of Aug. 06, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on TFBS Bioscience and its competitors. This is 37% below median its historical median of 0.93. Over the past decade, TFBS Bioscience's PB Ratio has ranged from 0.57 to 1.94. According to the industry distribution chart, TFBS Bioscience ranks #16 out of 195 companies in the Medical Diagnostics & Research industry, placing it in the top 8.2%.
Is TFBS Bioscience's PB Ratio too high?
TFBS Bioscience's current PB Ratio of 0.59 is 37% below median its 10-year median of 0.93. Over the past 10 years, this metric has ranged from a low of 0.57 to a high of 1.94. The Medical Diagnostics & Research industry median PB Ratio is 2.06. TFBS Bioscience's value of 0.59 is 71.4% below this industry median. Based on the distribution chart, TFBS Bioscience ranks #16 out of 195 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, TFBS Bioscience has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TFBS Bioscience's PB Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, TFBS Bioscience ranks #16 out of 195 companies for PB Ratio. This places TFBS Bioscience in the top 8% of its industry — outperforming the majority of peers. The industry median PB Ratio is 2.06. TFBS Bioscience's value of 0.59 is 71.4% below this benchmark. Historically, TFBS Bioscience's own PB Ratio has ranged from 0.57 to 1.94 over the past decade. While the company's 10-year median is 0.93 vs. the industry median of 2.06, TFBS Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Diagnostics & Research company?
The median PB Ratio among Medical Diagnostics & Research companies is 2.06, based on 195 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. TFBS Bioscience's current PB Ratio of 0.59 is 71.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on TFBS Bioscience and its competitors. For the Medical Diagnostics & Research industry, the median PB Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TFBS Bioscience's current PB Ratio is 0.59, which is 37% below median its own 10-year median of 0.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TFBS Bioscience stock overvalued right now?
Based on GuruFocus' analysis, TFBS Bioscience (ROCO:6939) is currently considered Possible Value Trap. The stock's GF Value™ is NT$31.94, compared to a current price of NT$19.45 — trading 39.1% below its estimated fair value. The current PB Ratio is 0.59, which is 37% below median its 10-year median of 0.93 and 71.4% below the Medical Diagnostics & Research industry median of 2.06. TFBS Bioscience's overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For TFBS Bioscience (ROCO:6939), the current PB Ratio is 0.59 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TFBS Bioscience (ROCO:6939) Overvalued in 2026?
Based on GuruFocus' analysis, TFBS Bioscience stock appears to be undervalued.
The current stock price of NT$19.45 is trading 39.1% below its estimated GF Value™ of NT$31.94.
GuruFocus considers TFBS Bioscience to be Possible Value Trap.
Key valuation signals for ROCO:6939:
PB Ratio: 0.59 (37% below median its 10-year median of 0.93)
GF Value™: NT$31.94 vs. price of NT$19.45 (39.1% below fair value)
Industry Position: 71.4% below the Medical Diagnostics & Research median (#16 of 195)
No single metric tells the full story. See the ROCO:6939 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TFBS Bioscience Inc is a Contract Research Organization (CRO) providing biological testing in Taiwan. Its services include viral vector manufacturing for cell and gene therapy products and biosafety testing and product release testing for cell and gene therapy products, vaccines, and biologic products.
48GF Score
Get the complete analysis for ROCO:6939
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6939 has been successfully added to your 
